Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Sym021 + Sym024 |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Sym021 | Sym-021|Sym 021 | Immune Checkpoint Inhibitor 149 PD-L1/PD-1 antibody 121 | Sym021 is a monoclonal antibody that targets PD-1 (PDCD1) and inhibits binding of the PD-L1 (CD274) ligand, potentially resulting in enhanced anti-tumor immune response (AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 3822, PMID: 31046547, PMID: 31754392). | |
Sym024 | Sym-024|Sym 024|S095024 | CD73 Antibody 12 | Sym024 is a monoclonal antibody against CD73, which may inhibit the conversion of AMP to adenosine, reducing adenosine-mediated immunosuppression (Cancer Res (2024) 84 (6_Supplement): 3737, NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04672434 | Phase I | Sym021 + Sym024 Sym024 | Sym024 Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies | Active, not recruiting | USA | CAN | 0 |